We have increasingly seen how oncologists like the efficacy associated with the immune checkpoint combination of ipilimumab plus nivolumab, but are leery of the increase in side effects, including immune related events.
Are there practical ways to reduce this phenomenon, other than dose reductions?
CytomX are one company who are focused on engineering a different concept with their monoclonal antibodies, bispecifics and ADCs to try and mask the effects, thereby reducing the treatment emergent toxicities. Their main idea is that the therapeutic window can be widened, thereby improving the tolerability profile.
It’s a nice idea, but what happens in practice?
To find out, we took a look at the recent early clinical data and interviewed executives from the company…